|
| |
Boehringer Ingelheim Pharmaceuticals, IncBoehringer Ingelheim Corporation is the U.S. member of the Boehringer Ingelheim worldwide group of companies dedicated to the discovery, development, manufacture and marketing of innovative human and animal health care products.
It is the principal U.S. licensee of Boehringer Ingelheim GmbH, an international chemical and pharmaceutical firm that develops, produces and sells pharmaceuticals, veterinary medicines and biologicals, agricultural chemical products and fine, specialty chemicals in more than 45 companies around the world. Worldwide sales for the Boehringer Ingelheim group of companies were $10.2 billion in 2004. The world's largest privately held pharmaceutical enterprise, Boehringer Ingelheim GmbH employs over 36,000 people.
Boehringer Ingelheim Corporation is the parent of a group of U.S. companies that produce ethical pharmaceuticals, natural health products, veterinary products and fine chemicals. Collectively, the U.S. Boehringer Ingelheim companies employ more than 7,200 people.
| Contact Details: |
| 900 Ridgebury Road/P.O. Box 368 |
| Ridgefield |
| Connecticut |
| 6877 |
| United States of America |
| Tel: | (203) 798-9988 |
| Fax: | (800) 243-0127 |
| Email: | koconno4@rdg.boehringer-ingelheim.com |
| WWW: | www.bi-usa.com/
|
|
Loading...
|
Press Releases on Boehringer Ingelheim Pharmaceuticals, Inc:
|
 |
| LATEST DATA ABOUT AN INVESTIGATIONAL DRUG FOR A FEMALE SEXUAL DYSFUNCTION RELEASED |
16th November, 2009 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
It is estimated that 1 in 10 American women suffer from decreased sexual
desire that causes interpersonal distress-a condition that could be
Hypoactive Sexual Desire Disorder (HSDD).
HSDD is
|
| Boehringer Ingelheim Announces Pivotal Phase III Data of Flibanserin in Pre-Menopausal Women with Hypoactive Sexual Desire Disorder |
16th November, 2009 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
RIDGEFIELD, Conn., Nov. 16 /PRNewswire/ -- Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the
|
| Video: Budding Videographers Vividly Portray Life with Diabetes to Mark World Diabetes Day |
10th November, 2009 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
-- Lorraine, CT
About Diabetes
Approximately 23.6(1) million Americans and 246 million people worldwide(2) have diabetes. Type 2 diabetes is the most common type, accounting for more than 90%
|
| FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure |
19th October, 2009 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
10. U.S. Centers for Disease Control and Prevention. Heart Disease and
Stroke Prevention.
http://www.cdc.gov/NCCDPHP/publications/AAG/dhdsp.htm. Accessed on
September 3,
|
| Boehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Clinical Program for linagliptin |
29th September, 2009 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
RIDGEFIELD, Conn., Sept. 29 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the conclusion of the linagliptin pivotal Phase III clinical trials, including more than 4,000
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 370 times since April 2007, the link to the organisation's website has been followed 64 times Search for more companies in Ridgefield Search for more companies in Connecticut This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Boehringer Ingelheim Pharmaceuticals, Inc |
